Ceftolozane/tazobactam

ApprovedSmall molecule

Merck & Co.

Ceftolozane/tazobactam is one of 116 small molecule programs targeting Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

Cystic FibrosisActive, not recruiting

Ventilator-Associated PneumoniaActive, not recruiting

Urinary Tract InfectionActive, not recruiting

PneumoniaPhase 1

Active, not recruiting

Cystic FibrosisApproved

Active, not recruiting

Ventilator-Associated PneumoniaPhase 3

Active, not recruiting

Urinary Tract InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Ceftolozane/tazobactam

Merck & Co.

Approved

3 2

Jakafi

Incyte

Preclinical

1 3

Retrovir

BBp Consulting, Inc

Preclinical

2 4

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 5

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 6

Advil

KKenvue Brands

Preclinical

2 7

Pepcid

KKenvue Brands

Preclinical

1 8

Aciphex

Akero Therapeutics

Preclinical

1 9

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 10

Alka-Seltzer

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia3 trials

Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02070757·726 enrolled

Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02387372·37 enrolled

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT04223752·41 enrolled

Cystic Fibrosis2 trials

Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis

Unknown status·—·Phase 4·NCT06035055·30 enrolled

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

Completed·JJoseph L. Kuti, PharmD·Phase 4·NCT02421120·21 enrolled

Intra-abdominal Infection2 trials

Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03830333·268 enrolled

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03217136·94 enrolled

Bacteremia1 trial

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

Recruiting·IInstituto Nacional de Cancerologia de Mexico·N/A·NCT06422533·226 enrolled

Ventilator-Associated Pneumonia1 trial

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT01853982·4 enrolled

8 more indications

Burns1 trial

Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns

Terminated·TTexas Tech University Health Sciences Center·Phase 4·NCT03002506·6 enrolled

Antibiotic Therapy1 trial

Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02266706·43 enrolled

SMA1 trial

Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients

Unknown status·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla··NCT04257812·20 enrolled

Urinary Tract Infection1 trial

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03230838·134 enrolled

Pseudomonas Aeruginosa1 trial

In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients

Unknown status·EEmilio Bouza··NCT04196608·1,005 enrolled

Critically Ill Patients1 trial

Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.

Unknown status·SSemmelweis University··NCT04352855·55 enrolled

Infections1 trial

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

Completed·HHartford Hospital·Phase 1·NCT02620774·16 enrolled

Tics1 trial

Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid

Completed·—·Phase 1/2·NCT03309657·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Ceftolozane/tazobactam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ceftolozane/tazobactam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ceftolozane/tazobactam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Ceftolozane/tazobactam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumonia3 trials

Cystic Fibrosis2 trials

Intra-abdominal Infection2 trials

Bacteremia1 trial

Ventilator-Associated Pneumonia1 trial

Burns1 trial

Antibiotic Therapy1 trial

SMA1 trial

Urinary Tract Infection1 trial

Pseudomonas Aeruginosa1 trial

Critically Ill Patients1 trial

Infections1 trial

Tics1 trial

References

Drug Info

Quick Facts

Related News